A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Inclusion Criteria

• •1. Patients who have given informed written consent.
• •2. Male or female subjects ≥18 years of age, at time of signing informed consent.
• •3. Subjects who are refractory to standard treatment, intolerant of standard treatment, for whom standard treatment does not exist, or who have refused standard treatment.
• •4. Patients with measurable disease according to RECIST version 1.1
• •5. Patients who have had the certaion periods between the date of completion of prior therapy and the date of enrollment
• •6. Subjects who agree to have a tumor biopsy as part of the baseline examination. Patients who have difficulty in performing a tumour biopsy and have agreed to submit a previously collected stored specimen.
• •7. Patients with an ECOG PS of 0 or 1 at baseline.
• •8. Patients with haematopoietic, hepatic, renal, cardiac and respiratory functions that meet certain criteria in a baseline test.
• •1\) Patients with pathologically diagnosed advanced or metastatic solid tumors.
• •1. Patients with pathologically diagnosed with advanced or metastatic esophageal cancer, or advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
• •2. Patients with pathologically diagnosed squamous cell carcinoma.
• •3. Patients who agree to undergo tumor biopsy after administration.
• •1. Patients with pathologically diagnosed with advanced or metastatic esophageal cancer.
• •2. Patients with pathologically diagnosed squamous cell carcinoma.
• •3. Patients who agree to undergo tumor biopsy after administration.
• •1. Patients with advanced or metastatic head and neck cancer whose primary site of origin is the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, or paranasal sinuses.
• •2. Patients with pathologically diagnosed squamous cell carcinoma.
• •3. Patients who agree to undergo tumor biopsy after administration.